X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2564) 2564
Book Chapter (54) 54
Conference Proceeding (4) 4
Book / eBook (3) 3
Dissertation (3) 3
Magazine Article (3) 3
Reference (2) 2
Newspaper Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1523) 1523
aptamers (899) 899
aptamers, nucleotide - chemistry (720) 720
animals (717) 717
aptamer (670) 670
aptamers, nucleotide - therapeutic use (610) 610
ligands (540) 540
biochemistry & molecular biology (485) 485
proteins (470) 470
deoxyribonucleic acid--dna (439) 439
cancer (419) 419
dna (411) 411
in-vitro selection (374) 374
aptamers, nucleotide - metabolism (363) 363
rna (342) 342
nanoparticles (311) 311
binding (306) 306
selex aptamer technique (303) 303
base sequence (298) 298
female (293) 293
selex (287) 287
medicine, research & experimental (281) 281
cell line, tumor (280) 280
aptamers, nucleotide - pharmacology (269) 269
selection (268) 268
chemistry, multidisciplinary (266) 266
aptamers, nucleotide - genetics (265) 265
mice (263) 263
male (259) 259
multidisciplinary sciences (247) 247
pharmacology & pharmacy (237) 237
ribonucleic acid--rna (233) 233
vascular endothelial growth factor a - antagonists & inhibitors (231) 231
protein binding (224) 224
research (222) 222
drug delivery systems (221) 221
nucleic acids (210) 210
medicine (204) 204
dna aptamers (199) 199
protein (197) 197
oligonucleotides (196) 196
ranibizumab (196) 196
biotechnology & applied microbiology (194) 194
analysis (193) 193
affinity (191) 191
nucleic acid conformation (189) 189
systematic evolution (189) 189
review (184) 184
aptamers, nucleotide - administration & dosage (183) 183
antibodies (182) 182
chemistry (182) 182
rna aptamers (181) 181
in-vitro (180) 180
chemistry, medicinal (176) 176
cells (172) 172
binding sites (168) 168
fluorescence (166) 166
science (166) 166
ophthalmology (164) 164
chemistry, analytical (162) 162
biology (161) 161
molecules (161) 161
research article (161) 161
health aspects (160) 160
molecular sequence data (159) 159
macular degeneration - drug therapy (158) 158
bevacizumab (157) 157
deoxyribonucleic acid (156) 156
therapy (156) 156
angiogenesis inhibitors - therapeutic use (154) 154
gene expression (153) 153
tumors (153) 153
biosensors (151) 151
molecular biology (151) 151
expression (150) 150
in-vivo (149) 149
nanoscience & nanotechnology (142) 142
treatment outcome (140) 140
drugs (139) 139
biotechnology (138) 138
inhibition (138) 138
nanotechnology (138) 138
recognition (138) 138
biochemistry (136) 136
endothelial growth-factor (132) 132
oncology (132) 132
drug delivery (131) 131
macular degeneration (131) 131
biochemical research methods (130) 130
selex aptamer technique - methods (130) 130
aptamers, nucleotide (129) 129
physiological aspects (127) 127
aged (126) 126
antibodies, monoclonal, humanized (125) 125
exponential enrichment (125) 125
cell biology (124) 124
thrombin (124) 124
biomarkers (123) 123
drug-delivery (121) 121
therapeutics (119) 119
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2592) 2592
German (20) 20
Japanese (19) 19
Spanish (9) 9
French (7) 7
Polish (6) 6
Portuguese (6) 6
Chinese (4) 4
Russian (4) 4
Czech (3) 3
Danish (2) 2
Dutch (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Cochrane database of systematic reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
DA VINCI | Macular Edema [drug therapy surgery] | Growth Factor [therapeutic use] | Humans | RANIBIZUMAB PLUS PROMPT | Receptors, Vascular Endothelial | RANDOMIZED CONTROLLED-TRIAL | Bevacizumab | DEFERRED LASER | Antibodies, Monoclonal, Humanized [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Recombinant Fusion Proteins [therapeutic use] | PEGAPTANIB SODIUM | Angiogenesis Inhibitors [therapeutic use] | Laser Coagulation [methods] | Ranibizumab | QUALITY-OF-LIFE | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | COST-EFFECTIVENESS | Triamcinolone [therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Antibodies, Monoclonal [therapeutic use] | Aptamers, Nucleotide [therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Network Meta-Analysis | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Quality of Life
Journal Article
Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 8, Issue 8, p. CD005139
Journal Article
Journal Article
Annual review of pharmacology and toxicology, ISSN 0362-1642, 1/2017, Volume 57, Issue 1, pp. 61 - 79
.... The first therapeutic aptamer was described 25 years ago. Thus far, one aptamer has been approved for clinical use, and numerous others are in preclinical or clinical development... 
therapeutics | aptamer | antidote | pharmacology | SELEX | STRANDED-DNA MOLECULES |